Top

Supportive Care in Cancer

Published in:

01-03-2008 | Original Article

Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study

Authors: Mark Hackbarth, Norbert Haas, Christina Fotopoulou, Werner Lichtenegger, Jalid Sehouli

Published in: Supportive Care in Cancer | Issue 3/2008

Abstract

Purpose

The study aimed to determine the prevalence of dermatological side effects and its impact on quality of life in patients receiving systemic chemotherapy for women’s cancers.

Materials and methods

A prospective study was conducted on patients with histologically confirmed advanced women’s cancers who were deemed candidates for adjuvant or palliative chemotherapy. Patients were systemically examined for skin, hair, and nail side effects. The impact of those side effects on their quality of life was assessed using the health-related quality of life score (HRQL).

Results

Between April 2001 and October 2001, 91 patients received 1 to 17 (median 4) courses of chemotherapy. Malignancies included breast cancer (n = 39, 43%), ovarian cancer (n = 32, 35%), cervical cancer (n = 12, 13%), endometrial cancer (n = 5, 6%), fallopian tube cancer (n = 2, 2%), and vaginal cancer (n = 1, 1%). Chemotherapy agents included taxanes (n = 42, 46%), PEG doxorubicin (n = 17, 7%), other anthracyclines (epirubicin and doxorubicin; n = 6, 19%), topotecan (n = 13, 14%), and other agents (n = 13, 14%). Overall incidence of skin, nail, and hair side effects was 86.8% (n = 79). Seventeen patients (18.7%) developed a palmo-plantar erythrodysesthesia (PPE), and nine of those (53%) were of grade 3 in common toxicity criteria scale (NCI). Twenty-one patients (23.1%) developed nail changes such as subungual hematomas, onycholysis, and leukonychias or nail loss, while 69 (75.8%) developed hair loss. There was a higher incidence of PPE in patients receiving chemotherapy for palliation rather than cure (percent over percent, p < 0.001, Fisher’s exact test). Using the HRQL score, skin changes were the most frequently reported unpleasant side effect (34.1%), and of those patients who developed PPE, this was reported by n = 8 (47%) as the most unpleasant.

Conclusions

Dermatological chemotherapy side effects are frequent after treatment of women’s cancers and have a major impact on quality of life as assessed by HRQL. Counseling of patients with women’s cancers and the profile of side effects of chemotherapeutic agents should be considered before considering an adjuvant or palliative chemotherapy regimen.

Anonymous (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 16(11):3537–3541

Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, Meszaros P, Rosso R (1997) Hand–foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 33(6):967–969PubMedCrossRef

Chiewchanvit S, Noppakun K, Kanchanarattanakorn K (2004) Mucocutaneous complications of chemotherapy in 74 patients from Maharaj Nakorn Chiang Mai Hospital. J Med Assoc Thail 87(5):508–514

Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC (2000) Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142(4):808–811PubMedCrossRef

Comandone A, Bretti S, La Grotta G, Manzoni S, Bonardi G, Berardo R, Bumma C (1993) Palmar–plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 13(5C):1781–1783PubMed

DeSpain JD (1992) Dermatologic toxicity of chemotherapy. Semin Oncol 19(5):501–507PubMed

Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL (2004) Oral dexamethasone attenuates doxil-induced palmar–plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94(2):320–324PubMedCrossRef

EORTC (2006) EORTC QLQ-C30 Questionnaire V3.0

Essex (2000) Caelyx, Wissenschaftliche Produktinformationen

10.

Fitzpatrick JE (1993) The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 20(1):1–14PubMedCrossRef

11.

Flory SM, Solimando DA Jr, Webster GF, Dunton CJ, Neufeld JM, Haffey MB (1999) Onycholysis associated with weekly administration of paclitaxel. Ann Pharmacother 33(5):584–586PubMedCrossRef

12.

Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19(4):424–436PubMedCrossRef

13.

Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19(14):3312–3322PubMed

14.

Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18(17):3093–3100PubMed

15.

Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J (1995) Hand–foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75(8):2169–2173PubMedCrossRef

16.

Halford S, Yip D, Karapetis CS, Strickland AH, Steger A, Khawaja HT, Harper PG (2001) A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 12(10):1399–1402PubMedCrossRef

17.

Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK (2004) Hand–foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 44(10):1166–1172PubMedCrossRef

18.

Hussain S, Anderson DN, Salvatti ME, Adamson B, McManus M, Braverman AS (2000) Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 88(10):2367–2371PubMedCrossRef

19.

Israel VP, Garcia A, Roman L, Muderspach L (1999) Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 78:143–147CrossRef

20.

Korac B, Buzadzic B (2001) Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. J Dermatol Sci 25(1):45–52PubMedCrossRef

21.

Link CJ Jr, Sarosy GA, Kohn EC, Christian MC, Davis P, Adamo DO, Reed E (1995) Cutaneous manifestations of Taxol therapy. Invest New Drugs 13(3):261–263PubMedCrossRef

22.

Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar–plantar erythrodysesthesia. Cancer Chemother Pharmacol 44(4):303–306PubMedCrossRef

23.

Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136(12):1475–1480PubMedCrossRef

24.

Makris A, Mortimer P, Powles TJ (1996) Chemotherapy-induced onycholysis. Eur J Cancer 32A(2):374–375PubMedCrossRef

25.

Molpus KL, Anderson LB, Craig CL, Puleo JG (2004) The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93(2):513–516PubMedCrossRef

26.

Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15(3):987–993PubMed

27.

NCI (1999) Common Toxicity Criteria, Version 2.0. 2.0 ed: http://ctep.info.nih.gov

28.

Obermair A, Binder M, Barrada M, Bancher-Todesca D, Asseryanis E, Kubista E (1998) Onycholysis in patients treated with docetaxel. Ann Oncol 9(2):230–231PubMedCrossRef

29.

Oskay-Oezcelik G, Lehmacher W, Könsgen D, Christ H, Kaufmann M, Lichtenegger W, Sehouli J (2007) Breast cancer patients’ expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients. Ann Oncol 18(3):479–484CrossRef

30.

Park YH, Ryoo BY, Lee HJ, Kim SA, Chung JH (2003) High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy. Ann Oncol 14(11):1691–1692PubMedCrossRef

31.

Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82(2):323–328PubMedCrossRef

32.

Salzberg M, Herrmann R (2000) Hand–foot syndrome (palmar–plantar erythrodysesthesia). Schweiz Med Wochenschr 130(40):1413–1416PubMed

33.

Sehouli J, Oskay-Oezcelik G (2004) Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer. ASCO 2004

34.

Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, de Wit R (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66(1):83–87PubMedCrossRef

35.

Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999) Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40(3):367–398 (quiz 399–400)PubMedCrossRef

36.

Tejada-Berges T, Granai CO, Gordinier M, Gajewski W (2002) Caelyx/doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2(2):143–150PubMedCrossRef

Title: Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study
Authors: Mark Hackbarth
Norbert Haas
Christina Fotopoulou
Werner Lichtenegger
Jalid Sehouli
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 3/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-007-0318-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer

Cancer and thrombosis: an increasingly important association

Central venous catheter-related thrombosis in cancer patients: what we know and what we need to know

Biomarkers for cancer cachexia: is there also a genetic component to cachexia?

Multinational Association of Supportive Care in Cancer

Self-reported taste and smell changes during cancer chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer